Myelofibrosis · Strategy & Intelligence

MF treatment is moving beyond symptom control toward disease modification, biologic segmentation and deeper response.

Coming out of EHA 2026, SAI sees the field shifting from a predominantly spleen- and symptom-focused paradigm toward one centered on disease modification, anemia control, mutation-defined segments, molecular endpoints and patient-reported outcomes.

Test an MF question with usSee the EHA 2026 perspective
Deep MF / MPN Experience
Experience across opportunity assessment, clinical pathway strategy, competitive positioning, launch planning and in-line support in myelofibrosis and related myeloproliferative neoplasms.
Insights in Minutes
Synthetic Users can rapidly pressure-test physician reactions to new combinations, anemia strategies, molecular endpoints and mutation-specific approaches.
MF Expertise + AI
Disease-area expertise enhanced by AI tools to interpret evidence, challenge assumptions and accelerate strategic decisions.
Bring us a live question
Expert overview

The MF field is becoming more biologically defined—and more strategically complex.

The treatment paradigm appears to be moving from a predominantly symptom- and spleen-focused approach toward one centered on disease modification, biologically defined patient segments, anemia control and deeper molecular endpoints.

What is changing
  • JAK inhibitor combinations are raising the frontline efficacy bar.
  • Anemia is becoming a core treatment-selection driver rather than a secondary supportive-care issue.
  • CALR-targeted therapy is introducing the possibility of clone-selective treatment.
  • VAF reduction, marrow fibrosis and clonal dynamics are increasingly used to support disease-modification narratives.
  • Patient-reported outcomes and phenotype-driven sequencing are gaining importance as chronic treatment options expand.
Strategic implication
The competitive bar is moving beyond SVR and symptom control.

Future differentiation may depend on whether an asset can affect anemia, molecular burden, fibrosis, disease progression, survival or a biologically defined patient segment—without adding unacceptable toxicity or treatment burden.

SAI perspective · EHA 2026

What we believe matters coming out of EHA 2026.

Our experts see five themes shaping development strategy, competitive positioning and future commercial opportunity in myelofibrosis.

Signal 01

JAK inhibitor backbone & combination-driven disease modification

  • JAK inhibitors remain the backbone, but differentiation is shifting toward combinations that improve spleen, symptoms and disease biology.
  • Selinexor + ruxolitinib and next-generation JAK strategies are being positioned to raise the frontline efficacy bar.
  • Key watchpoint: which combinations justify added toxicity, cost and chronic treatment burden?
Signal 02

Anemia, cytopenias & iron homeostasis

  • Anemia is becoming a treatment-selection driver rather than a secondary supportive-care issue.
  • Competing approaches target ACVR1/hepcidin, activin/BMP/SMAD, hemojuvelin and transfusion independence.
  • Momelotinib, luspatercept, DISC-0974 and elritercept anchor a growing anemia-defined segment.
Signal 03

Clone-selective & mutation-defined therapy

  • CALR-targeted therapy is emerging as the leading mutation-specific opportunity in MF.
  • INCA033989 data suggest potential spleen, symptom, anemia, marrow and mutCALR VAF responses.
  • Mutation-directed approaches could shift treatment earlier and fragment MF by driver biology.
Signal 04

Molecular endpoints & risk stratification

  • VAF reduction, marrow fibrosis and clonal dynamics increasingly support disease-modification narratives.
  • Peripheral-blood VAF shifts may not equal malignant stem-cell clearance.
  • Deeper sequencing and updated risk tools may refine patient selection and trial enrichment.
Signal 05

Patient-centric sequencing & PRO differentiation

  • Treatment choice is becoming more phenotype-driven across symptoms, spleen, anemia, platelets, molecular risk and prior JAKi exposure.
  • Post-JAKi, cytopenic and transfusion-dependent populations remain major unmet-need opportunities.
  • PROs and quality-of-life measures are gaining importance as chronic treatment options expand.
What our team is asking now

The questions we think matter now.

These are the strategic questions our MF team is actively pressure-testing as the field moves toward deeper response, biologic segmentation and more phenotype-driven treatment choice.

What will define the next frontline standard in MF, and can a JAK inhibitor combination meaningfully outperform monotherapy?
Higher efficacy barWhich combinations can improve SVR35/TSS50 while also affecting anemia, molecular burden, marrow fibrosis, progression or survival?
Benefit vs burdenWhat magnitude of incremental benefit will justify added toxicity, cost and chronic treatment burden?
Competitive questionCould selinexor + ruxolitinib establish combination therapy as preferred frontline treatment, or will care remain phenotype-driven?
Why it matters

The EHA 2026 SENTRY data support the potential for combined JAK-STAT/XPO1 inhibition to generate both clinical and molecular responses, raising the question of whether response depth can redefine frontline differentiation.

What evidence will physicians and regulators require before accepting a therapy as truly “disease modifying”?
Biologic endpointsWill VAF reduction, marrow fibrosis improvement, stem/progenitor cell depletion or molecular response correlate with meaningful long-term outcomes?
Clinical translationDoes disease modification ultimately need to show prolonged survival, delayed progression, less leukemic transformation or lower transplant requirement?
Measurement challengeHow should molecular endpoints be measured and standardized so that apparent response reflects true malignant clone reduction?
EHA 2026 highlighted an important caution: peripheral-blood VAF reduction may reflect changes in cell populations rather than true elimination of the malignant stem-cell clone.
Strategic implication

Competitive advantage may accrue to the companies that can demonstrate biologically credible disease modification rather than another surrogate response.

How will anemia become integrated into the core MF treatment algorithm rather than managed as a secondary complication?
Regimen choiceWill physicians select a JAK inhibitor with intrinsic anemia benefit or combine a JAK inhibitor with an anemia-directed agent?
Mechanism differentiationWhich approach will win: ACVR1 inhibition, activin/BMP/SMAD modulation, hepcidin/hemojuvelin targeting or another mechanism?
Meaningful thresholdHow much hemoglobin improvement or transfusion independence is required to change treatment choice?
EHA 2026 signals

Luspatercept in INDEPENDENCE, DISC-0974 in RALLY-MF, momelotinib through ACVR1/hepcidin modulation and elritercept highlight increasingly differentiated anemia strategies.

Will mutation-specific therapies fragment MF into biologically defined treatment segments?
CALR test caseCan CALR-directed therapy produce durable elimination of the malignant clone?
Treatment positionCould CALR-mutant patients receive a CALR-directed agent instead of—or in addition to—a JAK inhibitor?
Earlier interventionCould mutation-specific therapies move into earlier-stage disease before substantial fibrosis or symptomatic progression?
Why INCA033989 matters

Early spleen, symptom, anemia, marrow and mutCALR VAF responses provide an important proof-of-concept that clone-selective therapy may be feasible in MF.

Where will the greatest unmet need remain once additional frontline options become available?
After JAK inhibitionPost-JAK inhibitor failure, intolerance and suboptimal response remain strategically important segments.
Phenotype-defined needCytopenic, thrombocytopenic, transfusion-dependent and anemic MF may become distinct competitive spaces.
Biologic riskCALR, JAK2, MPL and high-risk mutation populations may create differentiated portfolio and indication opportunities.
Portfolio implication

As the frontline becomes more crowded, value may migrate toward specific disease phenotypes, resistance states and biologically defined subpopulations.

Synthetic Users · Example output

We pressure-tested the questions above with an MF KOL persona.

The perspectives below illustrate the depth of directional clinician insight that can be generated in minutes and then interpreted by SAI experts. These outputs are designed to sharpen hypotheses and identify where deeper validation is needed—not to substitute for broader primary research.

MF

Myelofibrosis KOL perspective

Academic hematology / MPN specialist persona

Customized Synthetic User · generated in minutes
01 · Frontline standardPhenotype-driven care is likely to persist
Question tested
What will define the next frontline standard in MF, and can a JAK inhibitor combination meaningfully outperform JAK inhibitor monotherapy?
A universal frontline combination may be unlikely unless it clearly outperforms across multiple dimensions—or dominates in a defined subpopulation.
Phenotype still mattersAnemia-predominant, splenomegaly-predominant, cytopenic, proliferative and high-risk phenotypes argue against a single universal regimen.
Differentiated JAK nichesMomelotinib has carved out an anemia-focused niche, while pacritinib is differentiated in severe thrombocytopenia.
High bar for combinationsIncremental SVR improvement alone may not be enough; clinicians may want PFS/OS benefit or meaningful molecular response with comparable tolerability.
“A combination strategy needs to either outperform across the board — which is a very high bar — or identify a molecular or clinical subpopulation where the combination's benefit is unambiguous.”
What this could mean for your asset

Frontline positioning should identify the exact phenotype or biologic context where the combination creates an unambiguous benefit rather than assuming combination therapy will become the default.

02 · Mutation-defined MFMolecular segmentation is real, but likely gradual
Question tested
Will mutation-specific therapies fragment MF into molecularly defined treatment segments?
CALR is the clearest near-term test of whether MF can evolve toward mutation-defined treatment, but early adoption may be additive before it becomes substitutive.
Compelling biologyCALR creates a therapeutically exploitable neoantigen, making the opportunity feel biologically distinct rather than incremental.
Combination firstA likely early model is JAK inhibition for spleen/symptoms plus CALR-directed therapy for deeper disease control.
Timeline is uncertainMolecular segmentation may be inevitable, but practice change could take years as durability and clonal elimination are proven.
“My overall take: MF will fragment molecularly — I'd estimate within the next decade we'll see at least CALR-mutant MF managed differently.”
What this could mean for your asset

CALR programs should define whether they are aiming to complement JAK inhibitors, replace them, or move earlier—and what evidence would support each position.

03 · Remaining unmet needPost-JAK, cytopenic disease remains the hardest problem
Question tested
Where will the greatest unmet need remain once additional frontline options become available?
The largest opportunity may remain in patients who fail or cannot tolerate JAK inhibition—especially those with cytopenias, transfusion dependence and high-risk biology.
Post-JAK failureCurrent options often remain palliative pivots rather than strategies that materially alter disease trajectory.
Cytopenic frustrationPatients can be caught between controlling spleen/symptoms and preserving blood counts.
Transformation preventionThere is almost no proactive treatment proven to reduce leukemic transformation risk despite improving risk stratification.
“If I had to distill it to a strategic recommendation: build for the post-JAK inhibitor cytopenic patient first, design trials that capture the suboptimal responder, and invest in the biology of transformation prevention.”
What this could mean for your asset

Portfolio strategy should test the post-JAK cytopenic segment, suboptimal responders and transformation-risk populations as distinct opportunities rather than treating “relapsed MF” as one market.

Get access to full answers to all questions

Talk with our MF experts about these and other insights into the landscape.

Illustrative Synthetic User output from a customized MF KOL persona. Use directionally and validate with broader research before treating as market consensus.

Start with the decision

What MF decision is on your desk right now?

Bring us the question. Our MF experts can combine deep disease-area experience, current competitive intelligence and Synthetic Users to rapidly pressure-test the issue, surface likely physician reactions, and help determine what you need to investigate next.

Test the question with our MF team.

Test your question with our MF teamSee a Synthetic Users demonstration